The development of PEM resistance in lung cancer with an ALK rearrangement is associated with the activation of the EGFR-HER family, which provides a rationale for the use of the pan-her inhibitor, afatinib, to overcome PEM-acquired resistance. This evidence concerns the gene EGFR and lung carcinoma.